Comparative Pharmacology
Head-to-head clinical analysis: HYDROGENATED ERGOT ALKALOIDS versus WIGRETTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROGENATED ERGOT ALKALOIDS versus WIGRETTES.
HYDROGENATED ERGOT ALKALOIDS vs WIGRETTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrogenated ergot alkaloids act as partial agonists/antagonists at α-adrenergic receptors, serotonergic (5-HT1B/1D) receptors, and dopaminergic receptors. They cause vasoconstriction by activating α-adrenoceptors and 5-HT receptors on vascular smooth muscle, and inhibit prolactin secretion via D2 receptor agonism.
Nicotine replacement therapy: binds to nicotinic acetylcholine receptors in the brain, releasing dopamine and providing nicotine to reduce withdrawal symptoms and cravings.
1 mg orally three times daily, or 0.3 mg intramuscularly or subcutaneously once daily.
1 mg sublingually as needed for smoking cessation, up to 4 times daily. Maximum daily dose: 4 mg.
None Documented
None Documented
2-3 hours for dihydroergotamine; 12-15 hours for ergoloid mesylates, requiring cautious dosing in hepatic impairment.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in moderate renal impairment.
Primarily hepatic metabolism (70-80%) with biliary excretion; renal excretion accounts for less than 10% of unchanged drug.
Renal excretion of unchanged drug accounts for 50-60% of the dose; biliary/fecal elimination accounts for 20-30%; remainder metabolized.
Category C
Category C
Ergot Alkaloid
Ergot Alkaloid